Related Experiment Video
Updated: Jun 14, 2026
10:42
A Protocol for the Production of Integrase-deficient Lentiviral Vectors for CRISPR/Cas9-mediated Gene Knockout in Dividing Cells
Published on: December 12, 2017
Toward integrase defective lentiviral vectors for genetic immunization
Donatella R M Negri1, Zuleika Michelini, Andrea Cara
1Department of Infectious, Parasitic and Immune-mediated Diseases, Istituto Superiore di Sanità, 00161, Rome, Italy.
Current HIV Research
|April 1, 2010
Summary
Genetic immunization using lentiviral vectors effectively induces sustained immune responses. These vectors offer safety benefits and are promising for clinical applications in gene therapy and vaccination.
Area of Science:
- * Immunology
- * Gene Therapy
- * Vaccinology
Background:
- * Genetic immunization aims to induce sustained immune responses.
- * Lentiviral vectors are explored for their potential in this area.
- * Existing vector platforms face challenges with immune responses and cell transduction.
Purpose of the Study:
- * To evaluate lentiviral vectors for genetic immunization.
- * To assess their ability to induce sustained immune responses.
- * To explore their safety and efficacy for clinical applications.
Main Methods:
- * Utilized lentiviral vectors for genetic immunization in vivo.
- * Assessed transduction of antigen-presenting cells (dendritic cells, macrophages).
- * Investigated induction of T-cell responses and antibody production.
- * Examined the use of integration-defective lentiviral vectors.
Main Results:
- * Lentiviral vectors demonstrated reduced anti-vector immune responses.
- * Efficient transduction of post-mitotic cells, including antigen-presenting cells, was observed.
- * A single immunization induced strong and sustained T-cell and antibody responses.
- * Integration-defective lentiviral vectors showed promise as safe delivery systems.
Conclusions:
- * Lentiviral vectors are effective for genetic immunization, inducing robust and lasting immunity.
- * Their ability to target antigen-presenting cells and reduced immunogenicity offer advantages.
- * Lentiviral vector-based strategies are suitable for safe clinical development in gene therapy and immunization.
